# Combination Chemotherapy in Patients With Zollinger-Ellison Syndrome and Tumors of the Pancreas

> **NCT00001165** · PHASE2 · COMPLETED · sponsor: **National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)** · enrollment: 999 (—)

## Conditions studied

- Islet Cell Adenoma
- Neoplasm Metastasis
- Zollinger Ellison Syndrome

## Interventions

- **DRUG:** combined chemotherapy with streptozotocin, 5-fluorouracil, and doxorubicin

## Key facts

- **NCT ID:** NCT00001165
- **Lead sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1978-09
- **Primary completion:** —
- **Final completion:** 2003-08
- **Target enrollment:** 999 (—)
- **Last updated:** 2008-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001165

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001165, "Combination Chemotherapy in Patients With Zollinger-Ellison Syndrome and Tumors of the Pancreas". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00001165. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*